Literature DB >> 28229243

Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy.

Hideaki Nakatsuji1, Amane Araki1,2, Atsushi Hashizume1, Yasuhiro Hijikata1, Shinichiro Yamada1, Tomonori Inagaki1, Keisuke Suzuki1,3, Haruhiko Banno1, Noriaki Suga1,4, Yohei Okada5,6, Manabu Ohyama7, Tohru Nakagawa8, Ken Kishida9,10, Tohru Funahashi9,11, Iichiro Shimomura9, Hideyuki Okano6, Masahisa Katsuno12, Gen Sobue13,14.   

Abstract

This study aimed to evaluate various metabolic parameters in patients with spinal and bulbar muscular atrophy (SBMA), to investigate the association between those indices and disease severity, and to explore the underlying molecular pathogenesis. We compared the degree of obesity, metabolic parameters, and blood pressure in 55 genetically confirmed SBMA patients against those in 483 age- and sex-matched healthy control. In SBMA patients, we investigated the correlation between these factors and motor functional indices. SBMA patients had lower body mass index, blood glucose, and Hemoglobin A1c, but higher blood pressure, homeostasis model assessment of insulin resistance (HOMA-IR, a marker of insulin resistance), total cholesterol, and adiponectin levels than the control subjects. There were no differences in visceral fat areas, high-density lipoprotein-cholesterol (HDL-C), or triglyceride levels in two groups. Revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) correlated positively with HDL-C, but negatively with HOMA-IR. Through stepwise multiple regression analysis, we identified HOMA-IR as a significant metabolic determinant of ALSFRS-R. In biochemical analysis, we found that decreased expressions of insulin receptors, insulin receptor substrate-1 and insulin receptor-β, in autopsied muscles and fibroblasts of SBMA patients. This study demonstrates that SBMA patients have insulin resistance, which is associated with the disease severity. The expressions of insulin receptors are attenuated in the skeletal muscle of SBMA, providing a possible pathomechanism of metabolic alterations. These findings suggested that insulin resistance is a metabolic index reflecting disease severity and pathogenesis as well as a potential therapeutic target for SBMA.

Entities:  

Keywords:  Insulin receptor; Insulin resistance; SBMA; Spinal and bulbar muscular atrophy

Mesh:

Substances:

Year:  2017        PMID: 28229243     DOI: 10.1007/s00415-017-8405-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

1.  Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ran S Rotem; Ryan M Seals; Ole Gredal; Johnni Hansen; Marc G Weisskopf
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

2.  Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract.

Authors:  Makoto Minamiyama; Masahisa Katsuno; Hiroaki Adachi; Hideki Doi; Naohide Kondo; Madoka Iida; Shinsuke Ishigaki; Yusuke Fujioka; Shinjiro Matsumoto; Yu Miyazaki; Fumiaki Tanaka; Hiroki Kurihara; Gen Sobue
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

3.  Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients.

Authors:  Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Masahiro Waza; Chen Sang; Yuji Nakagomi; Yasushi Kobayashi; Fumiaki Tanaka; Manabu Doyu; Akira Inukai; Mari Yoshida; Yoshio Hashizume; Gen Sobue
Journal:  Brain       Date:  2005-01-19       Impact factor: 13.501

Review 4.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

Review 5.  Polyglutamine androgen receptor-mediated neuromuscular disease.

Authors:  Elisa Giorgetti; Andrew P Lieberman
Journal:  Cell Mol Life Sci       Date:  2016-05-17       Impact factor: 9.261

6.  Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.

Authors:  L Dupuis; P Corcia; A Fergani; J-L Gonzalez De Aguilar; D Bonnefont-Rousselot; R Bittar; D Seilhean; J-J Hauw; L Lacomblez; J-P Loeffler; V Meininger
Journal:  Neurology       Date:  2008-01-16       Impact factor: 9.910

7.  Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

Authors:  Thomas Dehmer; Michael T Heneka; Magdalena Sastre; Johannes Dichgans; Jörg B Schulz
Journal:  J Neurochem       Date:  2004-01       Impact factor: 5.372

8.  Effects of prolonged fasting on AMPK signaling, gene expression, and mitochondrial respiratory chain content in skeletal muscle from lean and obese individuals.

Authors:  Marjolein A Wijngaarden; Gerard C van der Zon; Ko Willems van Dijk; Hanno Pijl; Bruno Guigas
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-19       Impact factor: 4.310

9.  Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females.

Authors:  Gianni Sorarù; Carla D'Ascenzo; Alberto Polo; Arianna Palmieri; Linda Baggio; Lodovica Vergani; Cinzia Gellera; Giuseppe Moretto; Elena Pegoraro; Corrado Angelini
Journal:  J Neurol Sci       Date:  2007-09-12       Impact factor: 3.181

10.  Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients.

Authors:  Giorgia Querin; Cinzia Bertolin; Elisa Da Re; Marco Volpe; Gabriella Zara; Elena Pegoraro; Nicola Caretta; Carlo Foresta; Maria Silvano; Domenico Corrado; Massimo Iafrate; Lorenzo Angelini; Leonardo Sartori; Maria Pennuto; Alessandra Gaiani; Luca Bello; Claudio Semplicini; Davide Pareyson; Vincenzo Silani; Mario Ermani; Alberto Ferlin; Gianni Sorarù
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-26       Impact factor: 10.154

View more
  14 in total

Review 1.  Genetic approaches to the treatment of inherited neuromuscular diseases.

Authors:  Bhavya Ravi; Anthony Antonellis; Charlotte J Sumner; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

2.  Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.

Authors:  Christopher Grunseich; Ram Miller; Therese Swan; David J Glass; Mohamed El Mouelhi; Mara Fornaro; Olivier Petricoul; Igor Vostiar; Ronenn Roubenoff; Matthew N Meriggioli; Angela Kokkinis; Robert D Guber; Maher S Budron; John Vissing; Gianni Soraru; Tahseen Mozaffar; Albert Ludolph; John T Kissel; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2018-10-15       Impact factor: 44.182

3.  The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy.

Authors:  Angela Rosenbohm; Susanne Hirsch; Alexander E Volk; Torsten Grehl; Julian Grosskreutz; Frank Hanisch; Andreas Herrmann; Katja Kollewe; Wolfram Kress; Thomas Meyer; Susanne Petri; Johannes Prudlo; Carsten Wessig; Hans-Peter Müller; Jens Dreyhaupt; Jochen Weishaupt; Christian Kubisch; Jan Kassubek; Patrick Weydt; Albert C Ludolph
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

Review 4.  Kennedy's disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease.

Authors:  Marianthi Breza; Georgios Koutsis
Journal:  J Neurol       Date:  2018-07-13       Impact factor: 4.849

5.  Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy.

Authors:  Robert D Guber; Varun Takyar; Angela Kokkinis; Derrick A Fox; Hawwa Alao; Ilona Kats; Dara Bakar; Alan T Remaley; Stephen M Hewitt; David E Kleiner; Chia-Ying Liu; Colleen Hadigan; Kenneth H Fischbeck; Yaron Rotman; Christopher Grunseich
Journal:  Neurology       Date:  2017-11-15       Impact factor: 9.910

6.  Tau deletion promotes brain insulin resistance.

Authors:  Elodie Marciniak; Antoine Leboucher; Emilie Caron; Tariq Ahmed; Anne Tailleux; Julie Dumont; Tarik Issad; Ellen Gerhardt; Patrick Pagesy; Margaux Vileno; Clément Bournonville; Malika Hamdane; Kadiombo Bantubungi; Steve Lancel; Dominique Demeyer; Sabiha Eddarkaoui; Emmanuelle Vallez; Didier Vieau; Sandrine Humez; Emilie Faivre; Benjamin Grenier-Boley; Tiago F Outeiro; Bart Staels; Philippe Amouyel; Detlef Balschun; Luc Buee; David Blum
Journal:  J Exp Med       Date:  2017-06-26       Impact factor: 14.307

Review 7.  Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease.

Authors:  Raquel Manzano; Gianni Sorarú; Christopher Grunseich; Pietro Fratta; Emanuela Zuccaro; Maria Pennuto; Carlo Rinaldi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-01-20       Impact factor: 10.154

8.  Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of italian patients with spinal-bulbar muscular atrophy.

Authors:  Francesco Francini-Pesenti; Giorgia Querin; Cristina Martini; Sara Mareso; David Sacerdoti
Journal:  Acta Myol       Date:  2018-09-01

Review 9.  Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.

Authors:  Frederick J Arnold; Diane E Merry
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 10.  Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review.

Authors:  Giorgia Querin; Peter Bede; Veronique Marchand-Pauvert; Pierre-Francois Pradat
Journal:  Front Neurol       Date:  2018-10-10       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.